Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma

BACKGROUND: Daratumumab is a human CD38‐directed monoclonal antibody indicated for the treatment of relapsed and refractory multiple myeloma (MM). METHODS: A multicenter, open‐label treatment protocol provided early access to daratumumab for patients who had progressive MM after they received ≥3 pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Chari, Ajai, Lonial, Sagar, Mark, Tomer M., Krishnan, Amrita Y., Stockerl‐Goldstein, Keith E., Usmani, Saad Z., Londhe, Anil, Etheredge, Delores, Fleming, Sarah, Liu, Baolian, Ukropec, Jon, Lin, Thomas S., Jagannath, Sundar, Nooka, Ajay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587745/
https://www.ncbi.nlm.nih.gov/pubmed/30395359
http://dx.doi.org/10.1002/cncr.31706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587745/
https://www.ncbi.nlm.nih.gov/pubmed/30395359
http://dx.doi.org/10.1002/cncr.31706

Ejemplares similares